This Buminate market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historical period can be attributed to regulatory frameworks, increased global healthcare spending, the expanding geriatric population, the rising incidence of trauma and burns, and heightened awareness of liver diseases.
Growth during the market's forecast period can be attributed to factors such as the rising prevalence of chronic diseases, growing adoption of recombinant albumin, the expansion of plasma collection networks, increased use in surgical and trauma care, and supportive government initiatives. Major trends in the forecast period include the integration of advanced technologies, the adoption of animal-free and recombinant technologies, advancements in plasma fractionation, and strategic partnerships and mergers.
The growing prevalence of liver diseases is expected to drive the expansion of the buminate market in the future. Liver diseases encompass a variety of conditions that impair liver function, including cirrhosis, hepatitis, fatty liver disease, and liver cancer. These conditions are often caused by factors such as infections, toxins, genetics, and chronic alcohol consumption. The global rise in liver diseases is attributed to increasing obesity rates, metabolic disorders, alcohol use, viral hepatitis, aging populations, and environmental influences. As a human albumin solution, Buminate helps manage liver diseases by restoring and maintaining blood volume and osmotic pressure in patients with conditions such as cirrhosis or liver failure. This improves circulation, supports fluid balance, and reduces the risk of complications such as edema and ascites. For example, in April 2024, the Office for Health Improvement and Disparities reported that in 2022, the mortality rate from liver disease in individuals under 75 in England rose to 21.4 per 100,000 population, with men experiencing 6,664 premature deaths compared to 3,929 for women. As a result, the rising prevalence of liver diseases is expected to drive growth in the buminate market.
The increase in healthcare expenditure is anticipated to further boost the buminate market in the coming years. Healthcare expenditure refers to the total spending on health services and related activities over a certain period, typically measured annually. This increase is driven by factors such as aging populations, the rising incidence of chronic diseases, higher service costs, technological advancements, increased demand, higher drug prices, the impact of COVID-19, medical inflation, and income disparities. Buminate benefits from higher healthcare spending, as greater investment in healthcare infrastructure and services leads to increased demand for effective treatments, such as buminate, particularly for managing conditions such as hypoalbuminemia and trauma. This results in broader market adoption, enhanced accessibility, and a steady revenue stream for both manufacturers and healthcare providers. For instance, in May 2024, the Office for National Statistics reported a 5.6% increase in healthcare spending in the UK between 2022 and 2023, compared to a growth of 0.9% in 2022. The total healthcare expenditure in the UK was around $317.63 billion (£292 billion) in 2023. Consequently, rising healthcare expenditure is fueling the growth of the buminate market.
The growing number of clinical trials is expected to further support the expansion of the buminate market. Clinical trials are research studies involving human participants designed to evaluate the safety, efficacy, and effectiveness of medical treatments, drugs, or devices. The number of clinical trials is increasing due to advancements in medical research, the rising incidence of chronic and complex diseases, and an aging global population that requires new treatments. Buminate benefits from clinical trials by providing essential data on its safety, efficacy, and potential new uses. This not only aids in its approval and adoption in various medical settings but also enhances physician confidence, expands its use across a wider range of conditions, and drives market demand and growth. For instance, in February 2024, ClinicalTrials.gov reported that the number of published clinical trials grew from 4,024 in 2022 to 5,063 in 2023. Therefore, the rise in clinical trials is contributing to the growth of the buminate market.
The key company operating in the buminate market is Grifols S.A.
North America was the largest region in the buminate market in 2024. The regions covered in buminate report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the buminate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Buminate is a brand name for a human albumin solution, a protein derived from human plasma. It is primarily used in medical treatments to restore or maintain circulating blood volume in patients who are experiencing shock, burns, trauma, or undergoing surgery. Buminate works by increasing the osmotic pressure in the blood, which helps draw fluid into the bloodstream, improving circulation and tissue perfusion.
The main indications for buminate include hypoproteinemia, burn treatment, and cardiopulmonary bypass surgery. Hypoproteinemia is a condition characterized by low protein levels, particularly albumin, in the blood. This can be caused by malnutrition, liver or kidney diseases, or severe burns. Buminate is distributed through hospital pharmacies, outpatient clinics, and specialty pharmacies, and is used by various end-users such as hospitals, clinics, ambulatory care centers, and home care settings.
The buminate market research report is one of a series of new reports that provides buminate market statistics, including buminate industry global market size, regional shares, competitors with a buminate market share, detailed buminate market segments, market trends and opportunities, and any further data you may need to thrive in the buminate industry. This buminate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The buminate market consists of sales of buminate 25% solution, pre-filled syringes and multi-dose vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historical period can be attributed to regulatory frameworks, increased global healthcare spending, the expanding geriatric population, the rising incidence of trauma and burns, and heightened awareness of liver diseases.
Growth during the market's forecast period can be attributed to factors such as the rising prevalence of chronic diseases, growing adoption of recombinant albumin, the expansion of plasma collection networks, increased use in surgical and trauma care, and supportive government initiatives. Major trends in the forecast period include the integration of advanced technologies, the adoption of animal-free and recombinant technologies, advancements in plasma fractionation, and strategic partnerships and mergers.
The growing prevalence of liver diseases is expected to drive the expansion of the buminate market in the future. Liver diseases encompass a variety of conditions that impair liver function, including cirrhosis, hepatitis, fatty liver disease, and liver cancer. These conditions are often caused by factors such as infections, toxins, genetics, and chronic alcohol consumption. The global rise in liver diseases is attributed to increasing obesity rates, metabolic disorders, alcohol use, viral hepatitis, aging populations, and environmental influences. As a human albumin solution, Buminate helps manage liver diseases by restoring and maintaining blood volume and osmotic pressure in patients with conditions such as cirrhosis or liver failure. This improves circulation, supports fluid balance, and reduces the risk of complications such as edema and ascites. For example, in April 2024, the Office for Health Improvement and Disparities reported that in 2022, the mortality rate from liver disease in individuals under 75 in England rose to 21.4 per 100,000 population, with men experiencing 6,664 premature deaths compared to 3,929 for women. As a result, the rising prevalence of liver diseases is expected to drive growth in the buminate market.
The increase in healthcare expenditure is anticipated to further boost the buminate market in the coming years. Healthcare expenditure refers to the total spending on health services and related activities over a certain period, typically measured annually. This increase is driven by factors such as aging populations, the rising incidence of chronic diseases, higher service costs, technological advancements, increased demand, higher drug prices, the impact of COVID-19, medical inflation, and income disparities. Buminate benefits from higher healthcare spending, as greater investment in healthcare infrastructure and services leads to increased demand for effective treatments, such as buminate, particularly for managing conditions such as hypoalbuminemia and trauma. This results in broader market adoption, enhanced accessibility, and a steady revenue stream for both manufacturers and healthcare providers. For instance, in May 2024, the Office for National Statistics reported a 5.6% increase in healthcare spending in the UK between 2022 and 2023, compared to a growth of 0.9% in 2022. The total healthcare expenditure in the UK was around $317.63 billion (£292 billion) in 2023. Consequently, rising healthcare expenditure is fueling the growth of the buminate market.
The growing number of clinical trials is expected to further support the expansion of the buminate market. Clinical trials are research studies involving human participants designed to evaluate the safety, efficacy, and effectiveness of medical treatments, drugs, or devices. The number of clinical trials is increasing due to advancements in medical research, the rising incidence of chronic and complex diseases, and an aging global population that requires new treatments. Buminate benefits from clinical trials by providing essential data on its safety, efficacy, and potential new uses. This not only aids in its approval and adoption in various medical settings but also enhances physician confidence, expands its use across a wider range of conditions, and drives market demand and growth. For instance, in February 2024, ClinicalTrials.gov reported that the number of published clinical trials grew from 4,024 in 2022 to 5,063 in 2023. Therefore, the rise in clinical trials is contributing to the growth of the buminate market.
The key company operating in the buminate market is Grifols S.A.
North America was the largest region in the buminate market in 2024. The regions covered in buminate report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the buminate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Buminate is a brand name for a human albumin solution, a protein derived from human plasma. It is primarily used in medical treatments to restore or maintain circulating blood volume in patients who are experiencing shock, burns, trauma, or undergoing surgery. Buminate works by increasing the osmotic pressure in the blood, which helps draw fluid into the bloodstream, improving circulation and tissue perfusion.
The main indications for buminate include hypoproteinemia, burn treatment, and cardiopulmonary bypass surgery. Hypoproteinemia is a condition characterized by low protein levels, particularly albumin, in the blood. This can be caused by malnutrition, liver or kidney diseases, or severe burns. Buminate is distributed through hospital pharmacies, outpatient clinics, and specialty pharmacies, and is used by various end-users such as hospitals, clinics, ambulatory care centers, and home care settings.
The buminate market research report is one of a series of new reports that provides buminate market statistics, including buminate industry global market size, regional shares, competitors with a buminate market share, detailed buminate market segments, market trends and opportunities, and any further data you may need to thrive in the buminate industry. This buminate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The buminate market consists of sales of buminate 25% solution, pre-filled syringes and multi-dose vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Buminate Market Characteristics4. Buminate Market Trends and Strategies5. Buminate Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Buminate Pricing Analysis & Forecasts30. Global Buminate Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Buminate Market32. Recent Developments in the Buminate Market
3. Buminate Market Biologic Drug Characteristics
6. Global Buminate Growth Analysis and Strategic Analysis Framework
8. Buminate Market Segmentation
9. Global Buminate Epidemiology of Clinical Indications
10. Buminate Market Regional and Country Analysis
11. Asia-Pacific Buminate Market
12. China Buminate Market
13. India Buminate Market
14. Japan Buminate Market
15. Australia Buminate Market
16. South Korea Buminate Market
17. Western Europe Buminate Market
18. UK Buminate Market
19. Germany Buminate Market
20. France Buminate Market
21. Eastern Europe Buminate Market
22. North America Buminate Market
23. USA Buminate Market
24. Canada Buminate Market
25. South America Buminate Market
26. Middle East Buminate Market
27. Africa Buminate Market
28. Buminate Market Competitive Landscape and Company Profiles
29. Global Buminate Market Pipeline Analysis
33. Buminate Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Buminate Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on buminate market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for buminate? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The buminate market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Hypoproteinemia; Burn Treatment; Cardiopulmonary Bypass Surgery2) by Distribution Channel: Hospital Pharmacies; Outpatient Clinics; Specialty Pharmacies
3) by End-Use: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Mentioned: Grifols S.a.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Grifols S.A.
